IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $535.00 at Bank of America

IDEXX Laboratories (NASDAQ:IDXX) had its price target upped by Bank of America from $475.00 to $535.00 in a research report report published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other brokerages have also weighed in on IDXX. Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Finally, Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $524.38.

IDEXX Laboratories Stock Down 0.9 %

NASDAQ IDXX opened at $465.03 on Tuesday. The stock’s 50 day simple moving average is $424.92 and its 200 day simple moving average is $453.54. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories has a one year low of $398.50 and a one year high of $583.39. The firm has a market cap of $38.08 billion, a PE ratio of 44.84, a price-to-earnings-growth ratio of 3.64 and a beta of 1.37.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.18% of the stock is owned by insiders.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds have recently bought and sold shares of the company. Algert Global LLC increased its position in shares of IDEXX Laboratories by 70.0% in the 2nd quarter. Algert Global LLC now owns 709 shares of the company’s stock valued at $345,000 after buying an additional 292 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in IDEXX Laboratories in the second quarter valued at about $1,363,000. Czech National Bank increased its holdings in shares of IDEXX Laboratories by 6.5% in the third quarter. Czech National Bank now owns 16,766 shares of the company’s stock worth $8,471,000 after acquiring an additional 1,028 shares in the last quarter. GAMMA Investing LLC raised its position in shares of IDEXX Laboratories by 26.8% during the third quarter. GAMMA Investing LLC now owns 1,484 shares of the company’s stock worth $750,000 after purchasing an additional 314 shares during the period. Finally, Mather Group LLC. lifted its holdings in shares of IDEXX Laboratories by 3.9% during the 3rd quarter. Mather Group LLC. now owns 617 shares of the company’s stock valued at $312,000 after purchasing an additional 23 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.